メニュー 戻るPresenters

8th DIA Cardiac Safety Workshop in Japan


Presenters

  • Kaori  Shinagawa, MD, PhD

    Kaori Shinagawa, MD, PhD

    • Senior Scientist for Clinical Medicine, Office of New Drug II
    • Pharmaceuticals and Medical Devices Agency (PMDA), Japan

    Dr. Kaori Shinagawa is Senior Scientist for Clinical Medicine, PMDA. She has been involved in clinical trial consultations and reviews of new drugs, assessments of cardiac safety of new drugs, and in creating new guidelines for Japanese drug applications. She has also been involved in ICH activities since 2005 including the E14 topic on clinical QT assessment. She is an executive committee member of the Cardiac Safety Research Consortium. She is a cardiologist and holds a doctoral degree of Medical Science. Dr Shinagawa's main research field was electrophysiology, and she has published in a variety of prestigious cardiovascular journals. She received the Kimura Memorial Award from the Japanese Heart Rhythm Society in 2000.

  • Yasunari  Kanda, PhD

    Yasunari Kanda, PhD

    • Head of Division of Pharmacology
    • National Institute of Health Sciences, Japan

    Dr. Kanda is Head of Division of Pharmacology, National Institute of Health Sciences. In this position, Dr. Kanda is responsible for all-japan project for cardiac safety assessment of human iPS cells. Dr. Kanda has over 20 years' experience in the pharmacology and toxicology field. Dr. Kanda hold a Ph. D. from the University of Tokyo and is also the recipient of the Metallomics Young Scientist Award for 2013.

  • Keita  Fujikawa

    Keita Fujikawa

    • Head of General Medicine, Japan Medical Office
    • Takeda Pharmaceutical Company Limited, Japan

  • Yuji  Kumagai, MD, PhD

    Yuji Kumagai, MD, PhD

    • Professor, Clinical Research Center
    • Kitasato University Hospital, Japan

    Dr. Yuji Kumagai is a clinical pharmacologist and he graduated from Oita University Faculty of Medicine in 1985. He got training on clinical pharmacology especially in cardiac drugs and received Ph.D degree in Oita University Graduate School of Medicine in 1989.He worked as an assistant professor at the department of Clinical Pharmacology, Jichi Medical University in 1989. After his several important works in the field of clinical pharmacology and chronobiology, he moved to Kitasato University in 1995 and concentrated on works in clinical trials. He has been a professor of Clinical Research Center,Kitasato University School of Medicine since 2011 and also the director of Clinical Trial Center at Kitasato University Hospital since 2013.

  • Atsushi  Sugiyama, MD, PhD

    Atsushi Sugiyama, MD, PhD

    • Professor and Chairman, Department of Pharmacology
    • Toho University Faculty of Medicine, Japan

    Dr. Sugiyama became a professor of Pharmacology of Toho University in April 2010 and remains active in the field of Cardiac Safety Pharmacology and its strategic direction. Dr. Sugiyama also maintains clinical practice as a cardiologist as well as a clinical pharmacologist. He has published over 170 peer-reviewed scientific original articles and is considered as an international expert of Cardiac Safety Pharmacology. He received his MD and PhD from Yamanashi Medical University, and is a Councilor of Japanese Pharmacological Society, Japanese Heart Rhythm Society and Japanese Safety Pharmacology Society.

  • Kyosuke  Takeshita, MD, PhD

    Kyosuke Takeshita, MD, PhD

    • Department of Clinical Laboratory Medicine
    • Saitama Medical Center, Saitama Medical University, Japan

    Kyosuke Takeshita, M.D., Ph.D., FAHA, is Associate Professor in the Departments of Clinical Laboratory, Nagoya University Hospital. In this position, Dr. Takeshita is responsible for managing education, research, and operational activities in clinical laboratory. Dr. Takeshita has over 20 years’ experience as a cardiology physician and a researcher of vascular biology. Dr. Takeshita has a special interest in biological mechanisms of systemic inflammation and thrombotic disorders, and assessment of physiological cardiovascular function. Dr. Takeshita earned PhD in Nagoya University School of Medicine, and is the recipients of YIA of the Japanese Circulation Association 2007, and Young Investigator Okamoto Award 2007.

  • Satoshi  Tsunoda

    Satoshi Tsunoda

    • Specialist, Office of New Drug IV
    • Pharmaceuticals and Medical Devices Agency (PMDA), Japan

  • Takashi  Yoshinaga

    Takashi Yoshinaga

    • Executive Director, Advanced Biosignal Safety Assessment
    • Eisai Co., Ltd., Japan

  • Börje C. Darpö, MD, PhD

    Börje C. Darpö, MD, PhD

    • Chief Scientific Officer, Cardiac Safety
    • ERT, Sweden

    Borje Darpo received is a board certified cardiologist since 1989. He specialized in clinical electrophysiology and presented his thesis on the clinical development of an antiarrhythmic drug in 1995. In 1998 he was appointed Fellow of the European Heart Association and in 2000 Associate Professor in Cardiology at the Karolinska Institute in Stockholm. In 1998 he joined Pharmacia and has held positions as Clinical Program Leader in Cardiovascular, Regional Head of EU for Clinical Pharmacology and Senior Director in Pfizer’s Clinical Technologies group in Sandwich, UK. Between April 2004 and March 2006, Dr Darpo held the position as Chief Medical Officer of Daiichi Medical Research in UK and USA.

  • Gary  Gintant, PhD

    Gary Gintant, PhD

    • Research Fellow
    • AbbVie Inc., United States

    Gary Gintant is a Research Fellow in the Dept. of Integrative Pharmacology, Global Pharmaceutical R&D, AbbVie. He is also a member of the CiPA Steering Committee and Co-Chair of the HESI Stem Celll-Cardiomyocyte Working Group.

  • Tadahiro  Shinozawa, PhD

    Tadahiro Shinozawa, PhD

    • Associate Director, Drug Safety Research Lab, Regenerative Medicine Unit
    • Takeda Pharmaceutical Company Limited, Japan

    Dr. Tadahiro Shinozawa is associate director of Drug Safety Research Laboratories and Regenerative medicine Unit at Takeda Pharmaceutical Company. In these positions, Dr. Shinozawa is responsible for leading the predictive toxicology group and T-CiRA PJ as Co-PI. Dr. Shinozawa has over 10 years' experience in the pharmaceutical industry and joined Cincinnati Children's Hospital Medical Center as a visiting scholar in 2016. Dr. Shinozawa holds a PhD in Agriculture from Tohoku University, and is also the recipient of Award of Graduate School of Agricultural Science in Tohoku University.

  • Katsuyoshi  Chiba, PhD

    Katsuyoshi Chiba, PhD

    • Senior Director and Head, Group III, Medicinal Safety Research Laboratories, R&D
    • Daiichi Sankyo Co., Ltd., Japan

  • Yoshito  Zamami

    Yoshito Zamami

    • Associate professor, Department of Clinical Pharmacology and Therapeutics,
    • Tokushima University Graduate School, Japan

  • Zhihua   Li, PhD

    Zhihua Li, PhD

    • Biologist, Div. of Applied Regulatory Science, Office of Clinical Pharmacology,
    • Food and Drug Administration, United States

  • Hideaki  Takahashi

    Hideaki Takahashi

    • Reviewer
    • Pharmacheuticals and Medical Devices Agency, Japan

  • Jörg  Täubel, MD, FFPM

    Jörg Täubel, MD, FFPM

    • Chief Executive Officer
    • Richmond Pharmacology Ltd., United Kingdom

    Dr Jörg Täubel is a medical practitioner and CEO of Richmond Pharmacology. He has worked in clinical pharmacology for 24 years, conducted more than 400 early phase studies ranging from first time in man to proof of concept and is author of over 50 publications in scientific journals with extensive experience in cardiology, neurology, gastroenterology and ethnic bridging studies. He is a Fellow of the Faculty of Pharmaceutical Medicine of the RCP (UK), the Institute of Directors and Honorary Fellow at St George's University London. He is a member of the AHPPI, the RSM, JSCPT and the ACCP, Regent of the AGAH and a founding member of EUFEMED. He lectures on the AGAH basic human pharmacology course and at the University Pompeu Fabra, Barcelona.

  • Boaz  Mendzelevski, MD

    Boaz Mendzelevski, MD

    • Consultant Cardiologist
    • Cardiac Safety Consultants Ltd., United Kingdom

お問い合わせ

Please contact DIA Japan for further information.

Send Email
+81.3.6214.0574